We have characterized the impact of strain-based genetic differences on the efficiency of intravenous (iv) cationic liposome:DNA complex (CLDC)-based gene transfer and expression in mice. We also investigated what steps in the gene delivery and expression pathway appeared responsible for these strain-related differences, and whether such differences could be compensated for either by agents that alter host pathways important in CLDC-mediated gene transfer and expression, or by changes in CLDC formulation.
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Summary
We have characterized the impact of strain-based genetic differences on the efficiency of intravenous (iv) cationic liposome:DNA complex (CLDC)-based gene transfer and expression in mice. We also investigated what steps in the gene delivery and expression pathway appeared responsible for these strain-related differences, and whether such differences could be compensated for either by agents that alter host pathways important in CLDC-mediated gene transfer and expression, or by changes in CLDC formulation.
We found that different mouse strains can exhibit different expression levels and/or differences in the amount of plasmid DNA delivered to the organs where the DNA is expressed. Furthermore, drug pretreatment or reformulation of the CLDC could improve DNA delivery, and/or gene expression in a strain-specific fashion. We conclude that genetic factors critically modify both the tissue deposition and the expression of genetic materials delivered by CLDC. Since manipulation of either the host or the CLDC could at least partially compensate for these strain-related differences, such strategies may be required to effectively use non-viral gene transfer approaches in genetically diverse populations.
Introduction
Recently, the discipline of pharmacogenics has shown that unique variations in genetic traits among individuals can produce substantial inter-individual variation in the disposition and metabolism of delivered drugs. Indeed, apparently mild polymorphisms can result in profound phenotypic differences among different individuals (1, 2) . Genetic polymorphisms also appear to affect in vivo gene delivery. However, studies to date have focused almost exclusively on differences in mouse strain-dependent acquired immune responses, and their effects on the duration of gene expression produced by recombinant viral vectors, as well as on the ability of these vectors to re-express heterologous genes upon re-injection of the virus (3) (4) (5) (6) (7) . The potential effects of genetic variations on the disposition and subsequent expression of genes delivered by non-viral carriers in vivo have not been reported.
Intravenous (iv) gene delivery requires a multi-step process of DNA transfer and expression events in order to transfect target tissues and cells. This process can be inhibited at one or more discrete steps, occurring anywhere from injection into the vascular compartment to expression in the nucleus of the transfected cell. In a 4 important role in regulating the efficiency of both iv, CLDC-based gene delivery and expression. We choose ICR (CD1) mice, an outbred strain commonly used for gene transfer experiments (8, 16, 20, 22, 25) , Swiss Webster mice as another outbred strain and FVB as an inbred line commonly used to generate knockout or transgenic mice (35).
FVB and Balb/c mouse strains, but not C57BL/6 mice have been reported to develop strain-specific humoral immunity against human apo A-1 following adenoviral-based delivery (4) . Similarly, CD1 but not C57BL/6 mice developed neutralizing humoralimmune responses against human factor IX following adenoviral-based delivery (6) .
Specifically, we assessed the effect on tissue luciferase activity of pre-treating groups of mice with A) dexamethasone, an agent with potent anti-inflammatory and glucocorticoid response element (GRE)-inducing activities (36) (37) (38) , B) ammonium chloride (NH4Cl), an inhibitor of lysosomal acidification, and thereby of DNA degradation within the lysosomal compartment (39) and C), ticlopidine, an inhibitor of platelet aggregation (40) , which may therefore alter the circulation dynamics of ivinjected CLDC (41) . We also assessed the effects of changing the diluent in which CLDC are formulated, inclusion of transcriptional regulatory elements contained in the expression vector, and the effect of changing the cationic lipid itself, on both the tissue uptake of the injected DNA, and the level of expression of iv-CLDC-delivered genes. 5 affinity glucocorticoid response elements (GREs) placed upstream of the adenovirus major late promoter TATA region (37) , was a gift from was Dr. J. White, McGill.
Preparation of cationic liposomes and CLDC. DOTIM:Cholesterol multilamellar vesicles(MLV) and DOGS-Cholesterol (MLV) were prepared as previously described (22, 23) .
CLDC diluent reformulation.
Four different CLDC diluent formulations, formulas A-D, were compared. Formula A (D5W) was prepared as described previously (22) .
Specifically, 40 µg of plasmid DNA complexed to either 640 nM of DOTIM:Cholesterol (total lipid) MLV or to 720 nM of DOGS:Cholesterol MLV were each dissolved in 100 µl D5W. The DNA and liposomes were then mixed together by adding the DNA solution to the liposome solution and the mixture was gently pipetted up and down twice. Formula B was prepared by dissolving the DNA in a 100 µl solution containing dextran 40 (Sigma) and lactated Ringer's solution at a ratio of 9:1 (volume:volume), the liposomes were dissolved in 100 µl of Ringer's solution, and the DNA and the liposome solution was mixed as above. Formula C was prepared by dissolving the DNA in 100 µl of fetal bovine serum (FBS) (Gemini, CA) and the liposomes in 100 µl of lactated Ringer's solution. injected IV in 200 µl of D5W. Twenty four hours after CLDC injection, mice were sacrificed in a CO 2 chamber. Heart, spleen lung and liver were collected and analyzed for either luciferase levels or DNA level by Southern analysis, as previously described (23).
Relative light units were converted to luciferase levels using a standard curve as 7 previously described (23). The potential statistical significance of differences was assessed using an unpaired, two sided Student's t test.
Measurement of tissue luciferase DNA levels by Southern blot analysis. Equal sized pieces of lung and liver were collected and prepared for Southern analysis as previously described (23). DNA was quantitated by phosphor imaging as previously described (23).
Statistical analysis. The potential statistical significance of differences in all experiments was assessed using an unpaired, two sided Student's t test.
Results
Luciferase plasmid DNA recovery and activity from various tissues after iv injection of CLDC in 3 different mouse strains. We first compared luciferase plasmid DNA delivery, as well as luciferase activity in three different mouse strains; two outbred (Swiss Webster and ICR/CD-1), and one inbred (FVB). All mice tested were female, of comparable size and age, obtained from the same vendor, and all were housed and fed under identical conditions. Twenty four hours after IV injection of DOTIM:Cholesterol MLV complexed to 40 µg of an HCMV-luc expression plasmid per mouse, tissues harvested from ICR mice showed significantly higher luciferase activities than either FVB or Swiss Webster mice (Fig. 1A) . Luciferase activity in the lungs of ICR mice was approximately 11 fold higher than in FVB mice (p < 0.0005) and 26 fold higher than in Swiss Webster mice (p < 0.0005). Spleens from ICR mice also showed approximately 6 and 9 fold higher luciferase activities than the spleens of FVB (p < 0.025) and Swiss Webster (p < 0.025) mice, respectively. Luciferase activity in the livers of ICR mice was 3.4 fold higher (p < 0.05) than found in the livers of Swiss Webster mice. Conversely, levels of tissue 8 luciferase activity in Swiss Webster and FVB mice (the low expresser strains) were similar in most tissues, and differed significantly (p < 0.025) only in spleen ( Fig 1A) .
Whereas the level of luciferase activity was significantly higher in ICR than FVB mice (Fig 1A) , levels of DNA delivery to tissues of these two strains were similar (Fig 1B) . In contrast, recovery of luciferase DNA from the lungs of Swiss Webster mice was approximately 2 fold lower than from the lungs of ICR mice (p < 0.005) and FVB mice (p < 0.05) (Fig 1B) . The ratio of gene expression level to DNA level in the lungs of Swiss Webster and FVB mice was quite similar, but was 12 fold higher in ICR mice. Therefore, strain-related differences in the expression of iv-CLDC-delivered genes can be caused either by differences in the overall tissue delivery, and/or by differences in the efficiency of expression of the iv-injected DNA expression vector.
Effects of drug pretreatment on the efficiency of iv, CLDC-based gene delivery among high-and low-expressor mouse strains. We next attempted to identify drug pretreatments that affect the efficiency of iv, CLDC-based gene transfer in a strain specific manner.
ICR mice pre-treated with dexamethasone showed substantially higher levels of gene expression in all tissues assayed, when compared to pretreatment with D5W alone (Figure 2A ). Specifically, luciferase activity was 2.9-fold higher in the lungs (p < 0.005), 5.3 fold higher in heart (p < 0.05), 4.5 fold higher in spleen, (p <0.005) and 3.6 fold higher in liver (p < 0.025) than in the ICR group receiving D5W pretreatment alone (Figure 2A ). In contrast, pretreatment of Swiss Webster mice with dexamethasone failed in most tissues assayed to increase luciferase activity ( Figure 2B ). Pre-treatment with ammonium chloride produced similarly low, but still statistically significant increases in tissue luciferase activity in both ICR and Swiss Webster mice ( Figure 2B ). Unlike 9 dexamethasone or ammonium chloride, pre-treatment with ticlopidine did not significantly alter the efficiency of iv, CLDC-gene delivery in either strain. Thus, of the three agents tested, both ammonium chloride and dexamethasone were able to increase expression levels. However, whereas ammonium chloride increased expression in both strains tested, the dexamethasone-mediated increase was specific to ICR mice.
Dexamethasone increases tissue delivery of luciferase DNA, as well as luciferase gene expression. Concurrently, we assessed whether dexamethasone, which increased iv, CLDC-based gene expression in ICR mice (Figure 2A ), significantly altered the tissue delivery of the HCMV-luc plasmid to either lung or liver of ICR or Swiss Webster mice.
Specifically, dexamethasone significantly (p < 0.05) increased the tissue delivery of pHCMV-luc DNA in the lung and liver of both ICR and Swiss Webster mice ( Figure   2C ). Thus, dexamethasone increased the localization but decreased the expression efficiency in Swiss Webster mice, whereas in ICR mice it increased both the localization of DNA and the expression efficiency.
The ability of dexamethasone to increase the expression of iv-injected CLDC is not due to the effects of GREs within the HCMV promoter. Previously, the HCMV promoter has been shown to contain multiple repeat sequences with significant homology to consensus GRE sequences (38) . Therefore, we assessed whether these putative GRE-elements within the HCMV promoter might be responsible for the significant induction of iv, CLDC-based gene expression in ICR mice due to the presence of dexamethasone ( Figure   2A ). To test this hypothesis, we used pGRE5-luc, an expression plasmid containing a minimal synthetic promoter consisting of five high-affinity GREs placed upstream of the adenovirus major late promoter TATA region. Gene expression from this promoter has 10 been shown to be increased from 10 to > 50 fold in cultured cells in the presence of dexamethasone (37) . To insure that the concentration of the glucocorticoid receptor (GR)
was not rate-limiting in either cells or animals, we tested the dexamethasoneresponsiveness of the pGRE5-luc plasmid, either alone, or co-transfected with pRSV-GR, containing the RSV promoter/enhancer linked to the rat GR (36). The low, baseline level of gene expression from pGRE5-luc in B16 melanoma cells co-transfected with pRSV-GR was increased 489 fold in the presence of dexamethasone ( Figure 3A) . Conversely, the high baseline level of gene expression from p4377, pHCMV-luc, in B16 cells cotransfected with pGRE5-luc was increased was less than 2 fold in the presence of dexamethasone ( Figure 3A ). These cell transfection experiments verified pGRE5-luc to be a highly dexamethasone-responsive, whereas the HCMV-luc vector showed minimal dexamethasone responsiveness in cultured cells.
We then tested the dexamethasone responsiveness of both the pGRE5-luc and pHCMVluc plasmids, following their iv, CLDC-based injection into ICR mice. As expected, in the absence of dexamethasone, the HCMV-driven expression plasmid produced substantial levels of tissue luciferase activity, whereas the minimal promoter-GRE-driven expression plasmid, co-injected with a CAT gene reporter plasmid produced very low levels of tissue luciferase activity. However, unlike the results obtained in cultured cells (Figure 3A) , dexamethasone-pretreatment of ICR mice significantly (p < 0.05) increased gene expression from iv-injected pHCMV-Luc, but had little effect on the expression of pGRE5-luc ( Figure 3B ). Overall, dexamethasone significantly induced gene expression from pGRE5-luc, but not from pHCMV-luc in cultured cells, whereas it increased gene expression from pHCMV-luc, but not from pGRE5-luc in ICR mice.
The effect of different CLDC diluents on the efficiency of CLDC-based IV gene delivery. Figure 4 shows the activity of iv, CLDC formulated in either 5%w/v glucose, (our customary diluent), or in one of three modified diluents described in the materials and methods section. When compared to CLDC formulated in D5W, CLDC formulated in either of the other three diluents produced significantly higher levels of luciferase activity in Swiss Webster mice (Fig 4A) . The levels of luciferase activity in the lungs of Swiss Webster mice were approximately 21 fold higher for CLDC diluted in dextran/Ringer's (p < 0.05), and approximately 3.5 fold higher for CLDC diluted in fetal bovine serum (FBS)/Ringer's (p < 0.05), when compared to mice receiving CLDC diluted in the standard D5W solution. Luciferase activities were also significantly higher in heart (p < 0.05), spleen (p < 0.025) and liver (p < 0.025) in Swiss Webster mice injected with CLDC diluted in dextran/Ringer's. CLDC diluted in dextran/Ringer's and FBS/D5W/Ringer's also produced significantly higher levels of luciferase activity in the spleens of Swiss Webster mice, but to a lesser extent than CLDC diluted in dextran/Ringer's ( Figure 4A) . Conversely, the use of these alternative diluents generally did not significantly alter luciferase activities in tissues from ICR mice, when compared to D5W ( Figure 4B ). These data suggest that, at least in some cases, reformulating CLDC can selectively convert the low-expressor phenotype (here Swiss Webster mice) towards the high-expressor phenotype (here ICR mice). 
Discussion
In the present study, we have found reproducible differences in the efficiency of both the delivery and the expression of iv, CLDC-injected genes among these different mouse strains. ICR/CD-1 mice expressed iv, CLDC-injected genes significantly (p < 0.05) more efficiently in a variety of tissues than did either Swiss Webster or FVB mice (Figure 1 ).
The more efficient expression of genes injected into ICR mice appeared to be due both to delivery-related and expression-related events. Furthermore, the relative importance of delivery versus expression in determining the overall efficiency of iv injected CLDC appeared to be mouse strain-specific. For example, the level of tissue delivery of the injected expression plasmid was similar between ICR and FVB mice ( Figure 1B) . However, ICR mice appeared able to express plasmid DNA already resident in tissues more efficiently than did FVB mice. Conversely, both the tissue delivery and expression of injected genes were higher in ICR than Swiss Webster mice (Figure 1) . Although FVB and Swiss Webster mice showed a similar expression efficiency of iv, CLDC-delivered genes ( Figure 1A) , DNA localized two times more efficiently in FVB mice ( Figures 1A   and B) . Thus, factors limiting the efficiency of iv, CLDC-based gene delivery appeared to be due to limitations imposed both by restricted tissue delivery as well as by the restricted expression of genes already taken up by tissues.
These studies demonstrate that mouse strain-related genetic differences influence both the tissue delivery and subsequent expression of genes injected intravenously by CLDC.
They suggest that human inter-individual genetic differences may play an important role in determining the efficiency of gene therapy, as they have been shown to do in drug therapy (1, 2) . Therefore, we assessed whether selective modification of either host factors or CLDC formulation could compensate for genetically based differences in the efficiency of iv, CLDC-based gene delivery. We found that pre-injection of either dexamethasone or ammonium chloride (Figure 2) , as well as reformulating CLDC in a combination of dextran-40 and lactated Ringer's solution rather than D5W (Figure 4) shifted gene transfer efficiency in low-expressor Swiss Webster mice towards that of high expressor, ICR mice. These results suggest that a variety of alternative, non-viral gene transfer strategies may be required in order to compensate for inter-individual genetic differences that control the overall efficiency of this approach.
Our results show that the host factors responsible for genetically-based, inter-individual differences gene transfer efficiency in whole animals are complex. Clearly, a more precise understanding of the specific cellular genes that regulate the trafficking and expression of injected DNA is required. Innate immune-response genes provide an example of candidate genes that may play a role in mediating strain-related differences in CLDC-based systemic gene transfer and expression. Differences in immune responsiveness may be one host factor that could account for the strain-related differences in the efficiency of iv, CLDC-mediated gene transfer and expression. For example, strain-related differences in immune responses have already been shown to play a significant role in regulating the duration of expression of genes delivered by recombinant viral vectors (3) (4) (5) (6) (7) . In many of these cases, lymphocytes and acquired immune responses play a critical role, particularly with respect to repeated gene delivery.
In the case of iv CLDC gene delivery, however, the differences in gene expression occurred within 24 hours of the first gene delivery, which appears to be too soon for acquired immunity to play a significant role. CLDC have been reported to be potent inducers of innate immune responses, including release of pre-inflammatory cytokines and activation of macrophages, dendritic cells, and NK cells (13, 21, 31, 43, 44) . For example, TNF-α has been reported to play a key role in regulating the level of gene expression after in vivo delivery using CLDC (21, 31) . Therefore, it is possible that the strain-related differences in gene expression observed in the studies reported here might be due, at least in part to differences in the relative sensitivities of innate immune responses to CLDC.
However, given the very large number of cellular genes that could regulate the 'transfection permissive phenotype', identifying the specific gene or genes responsible will be difficult. Furthermore, the use of germline mutant mouse models to identify genes ammonium chloride, as described in materials and methods. Twenty four hours after IV-CLDC, mice were sacrificed and heart, liver and lung tissues were collected and assayed for luciferase activity. Luciferase activity is shown as the mean + standard SEM, using a student's two-sided T-test to determine the significance of differences. CLDC-pHCMV-luc plus pHCMV-CAT with D5W pretreatment, iii) CLDC-pHCMV-luc plus pHCMV-GR with dexamethasone pretreatment, iv) CLDC-pHCMV-luc plus pHCMV-GR with D5W pretreatment, v) CLDC-pGRE-luc plus pHCMV-CAT with dexamethasone pretreatment, vi) CLDC-pGRE-luc plus pHCMV-CAT with D5W pretreatment, vii) CLDC-pGRE-luc plus luc-GRE-luc with dexamethasone pretreatment, or viii) CLDC-pGRE-luc plus luc-GRE-luc with D5W pretreatment intravenously.
Twenty four hours after IV-CLDC, mice were sacrificed and heart, liver and lung tissues were collected and assayed for luciferase activity. Luciferase activity is shown as the mean + standard SEM, using a student's two-sided T-test to determine the significance of differences. FBS/D5W, as described in materials and methods. Twenty four hours after IV-CLDC, mice were sacrificed and heart, liver and lung tissues were collected and assayed for luciferase activity. Luciferase activity is shown as the mean + standard SEM, using a student's two-sided T-test to determine the significance of differences. quantitated by Southern analysis and phosphorimaging. DNA units are shown as the mean + standard SEM, using a student's two-sided T-test to determine the significance of differences. (B) Heart, liver and lung tissues were collected from these same groups of mice and assayed for luciferase activity. Luciferase activity is shown as the mean + standard SEM, using a student's two-sided T-test to determine the significance of differences.
